- Home
- EBS vs AURA Comparison
EBS vs AURA Comparison
Compare EBS & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBS
- AURA
- Stock Information
- Founded
- EBS 1998
- AURA 2007
- Country
- EBS United States
- AURA United States
- Employees
- EBS N/A
- AURA N/A
- Industry
- EBS Biotechnology: Pharmaceutical Preparations
- AURA Biotechnology: Pharmaceutical Preparations
- Sector
- EBS Health Care
- AURA Health Care
- Exchange
- EBS Nasdaq
- AURA Nasdaq
- Market Cap
- EBS 359.3M
- AURA 396.8M
- IPO Year
- EBS 2006
- AURA 2021
- Fundamental
- Price
- EBS $9.23
- AURA $6.55
- Analyst Decision
- EBS Strong Buy
- AURA Strong Buy
- Analyst Count
- EBS 3
- AURA 7
- Target Price
- EBS $14.33
- AURA $22.29
- AVG Volume (30 Days)
- EBS 1.5M
- AURA 156.0K
- Earning Date
- EBS 08-06-2025
- AURA 08-13-2025
- Dividend Yield
- EBS N/A
- AURA N/A
- EPS Growth
- EBS N/A
- AURA N/A
- EPS
- EBS 2.53
- AURA N/A
- Revenue
- EBS $851,600,000.00
- AURA N/A
- Revenue This Year
- EBS N/A
- AURA N/A
- Revenue Next Year
- EBS $14.20
- AURA N/A
- P/E Ratio
- EBS $3.65
- AURA N/A
- Revenue Growth
- EBS N/A
- AURA N/A
- 52 Week Low
- EBS $4.02
- AURA $4.35
- 52 Week High
- EBS $12.73
- AURA $12.38
- Technical
- Relative Strength Index (RSI)
- EBS 68.42
- AURA 47.00
- Support Level
- EBS $8.91
- AURA $6.10
- Resistance Level
- EBS $9.43
- AURA $7.40
- Average True Range (ATR)
- EBS 0.59
- AURA 0.38
- MACD
- EBS 0.15
- AURA -0.06
- Stochastic Oscillator
- EBS 88.89
- AURA 34.62
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.